Bitmine to Stop Ethereum Buying After Reaching 5% ETH Supply 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Securitize, LG CNS Partner on South Korea Tokenization 
Gold Prices Rise as Dollar Weakens, Treasury Yields Ease 
US Stock Futures Flat as Fed Minutes, Earnings Loom 
Dollar Retreats From 18-Month High as Euro Rebounds 
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal 
European Stocks Diverge as French Fiscal Crisis Hits CAC 40 
Constellation Brands Beats Q2 Estimates, Buys SpikedAde 
Circle Stock Falls 4% as Crypto Selloff Overshadows SAP Pay Expansion 
Rapidus Seeks Chip Customers as Japan Pushes 2nm Semiconductor Revival 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
German Industrial Orders Plunge 10.6% in August 
Kalshi Withdraws PEPE Perpetual Futures Filing 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Paramount Skydance Completes $110 Billion Warner Bros Discovery Deal 
Anthropic Expands Claude Access for Cyber Defense Teams 
Add as a preferred source on Google
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
